A federal judge in Colorado approved a $3.575 million settlement in July 2025 in a class action lawsuit against Similasan Corporation, the maker of homeopathic eye drop products sold under the Similasan brand and at retailers including CVS and Walgreens. The settlement resolves allegations that the company falsely labeled and marketed its eye drops as homeopathic remedies without FDA approval, while also failing to follow proper manufacturing standards. If you purchased Similasan eye drops, store-brand homeopathic eye drops from CVS, or Walgreens homeopathic eye drops between September 11, 2017 and February 20, 2025, you likely qualify for compensation. Nearly 100,000 claims have been filed through the settlement, and instead of the base compensation of $2.50 per product, eligible class members have been receiving substantially more—around $14.63 per product—because fewer people than anticipated submitted claims.
For example, if you bought three boxes of Similasan eye drops during the covered period, you could receive roughly $44 in compensation. Settlement payments are being distributed via virtual prepaid Mastercard, direct deposit, Zelle, Venmo, or check, depending on your preference. The lawsuit centered on Similasan’s misleading marketing claims about the “homeopathic” status of its eye drops, along with undisclosed safety risks and manufacturing defects. The company did not admit wrongdoing, which is standard in class action settlements, but agreed to pay to resolve the claims.
Table of Contents
- Why Was There a Class Action Lawsuit Against Similasan Eye Drops?
- What Manufacturing and Safety Issues Were Alleged?
- How Much Money Did Eligible Consumers Receive from the Settlement?
- What Was the Deadline to File a Claim, and Did You Miss It?
- Which Eye Drop Products Are Covered by the Settlement?
- What Happened to Similasan After the Settlement?
- What Does This Settlement Mean for Homeopathic Products Generally?
- Conclusion
Why Was There a Class Action Lawsuit Against Similasan Eye Drops?
The lawsuit targeted multiple forms of deception in how Similasan marketed and manufactured its eye drop products. The core allegation was that Similasan labeled its eye drops as “homeopathic” products without obtaining FDA approval for homeopathic classifications. Under federal law, homeopathic drugs are regulated differently than conventional over-the-counter medications, and manufacturers must comply with specific FDA standards. By claiming homeopathic status without approval, Similasan was allegedly misleading consumers about the regulatory scrutiny and testing the product had undergone.
Beyond the homeopathic labeling issue, the settlement also addressed manufacturing concerns. The plaintiffs alleged that Similasan’s eye drops were not manufactured in accordance with Current Good Manufacturing Practices (CGMP), which are FDA standards that ensure products are made safely, consistently, and with proper quality controls. Additionally, the lawsuit cited misleading “sterile” claims on the packaging and the failure to adequately disclose the presence of silver sulfate, an ingredient that could pose risks to consumers. A consumer who saw “homeopathic” on the label and assumed the product met FDA standards for that designation would have been misled about what kind of regulatory review the product actually received.
What Manufacturing and Safety Issues Were Alleged?
The lawsuit went beyond labeling problems to raise questions about how Similasan actually manufactured its eye drops. The allegation that products were not made according to CGMP standards is significant because these practices are foundational to pharmaceutical manufacturing quality. CGMP standards cover everything from ingredient purity and equipment sanitation to testing and documentation. When a manufacturer doesn’t follow these standards, there’s a heightened risk of contamination, inconsistent potency, or other quality failures that could affect consumer safety.
The inclusion of silver sulfate as an undisclosed ingredient was another concern highlighted in the settlement. While silver sulfate has been used in some ophthalmic products, consumers deserve to know what ingredients they’re putting in or around their eyes. The failure to clearly disclose this ingredient—particularly when marketing the products as homeopathic remedies, which consumers might assume contain only certain types of natural substances—represented a transparency failure. This type of omission is especially problematic for consumers with known sensitivities or allergies who need complete ingredient information to make informed decisions.
How Much Money Did Eligible Consumers Receive from the Settlement?
The settlement was structured with a base compensation amount of $2.50 per product purchased, with a maximum of $10 per household for those who could not provide proof of purchase. For consumers with receipts documenting their purchases, the per-product amount applied regardless of household purchase volume. However, the actual payout amounts ended up being significantly higher than originally projected—roughly $14.63 per product—because the settlement claims administrator received fewer claims than anticipated. This discrepancy between estimated and actual payouts is important to understand.
When a class action settlement is negotiated, the parties estimate how many class members will file claims and calculate per-person payouts based on that estimate. If fewer people claim than expected, the per-person payout increases because the total settlement money gets divided among fewer recipients. A consumer who purchased five bottles of Similasan eye drops during the covered period would have received approximately $73 under the higher actual payout rate, compared to an estimated $12.50 base amount. Settlement payments were distributed through multiple methods to accommodate different preferences: virtual prepaid Mastercard, direct deposit, Zelle, Venmo, or traditional check.
What Was the Deadline to File a Claim, and Did You Miss It?
The deadline to submit a claim was October 15, 2025, which has now passed. This means if you did not file a claim by that date, you are no longer eligible to receive compensation from the settlement, with extremely limited exceptions. Class action settlements typically have firm deadlines for claim submission because the settlement administrator needs to process and verify claims within a defined timeframe, and because the settlement agreement itself specifies when claim funds must be distributed to valid claimants.
If you purchased Similasan eye drops during the coverage period (September 11, 2017 through February 20, 2025) but missed the October 15, 2025 deadline, your opportunity for compensation from this particular settlement has passed. The only potential exception would be if you had extraordinary circumstances that prevented you from learning about or filing the claim—a concept called “excusable neglect”—but such exceptions are rarely granted and require court action. To avoid missing future settlement deadlines, monitor settlement websites regularly, sign up for class action notifications, and consult settlement claim websites for exact deadline dates rather than relying on memory or informal sources.
Which Eye Drop Products Are Covered by the Settlement?
The settlement covers Similasan brand homeopathic eye drops, as well as store-brand homeopathic eye drops sold at CVS and Walgreens during the covered period. Specifically, eligible products are those marketed as homeopathic eye drops under these brands. The coverage period was September 11, 2017 through February 20, 2025, which is a substantial timeframe—nearly eight years. This lengthy coverage period means that anyone who purchased these products at any point during that window and still has records of the purchase could have filed a claim.
One important limitation is that the settlement only covers eye drops purchased during the specified period. If you purchased Similasan eye drops before September 11, 2017 or after February 20, 2025, those purchases would not be eligible for compensation under this settlement. Additionally, the settlement specifically targets homeopathic eye drops from these retailers; other Similasan products (such as their cold and flu remedies or other non-eye-drop products) are not covered. For anyone trying to determine if a specific eye drop product qualifies, the safest approach is to check the official settlement website or contact the claims administrator to verify the exact product SKU or packaging.
What Happened to Similasan After the Settlement?
While the settlement imposed financial liability on Similasan Corporation, the company did not admit any wrongdoing as part of the agreement. This is typical in class action settlements—defendants often settle to avoid the cost and uncertainty of litigation without conceding that their conduct was illegal or unethical. The settlement amount of $3.575 million, while meaningful to consumers receiving compensation, represents the defendant’s calculation of the cost of litigation and settlement weighed against potential liability.
The practical outcome for consumers is that they received compensation for their purchases of products marketed with allegedly deceptive labeling and manufacturing claims. For Similasan specifically, the settlement may prompt changes in how the company labels and manufactures eye drops going forward, though the settlement itself does not impose explicit mandatory changes to future product labeling or manufacturing practices. Consumers who used Similasan eye drops and experienced any adverse effects should consult with their healthcare provider; a separate personal injury claim might be possible independently of this class action settlement.
What Does This Settlement Mean for Homeopathic Products Generally?
The Similasan settlement is one of several class action cases involving questionable homeopathic claims in recent years. This settlement highlights an ongoing tension in the regulatory landscape: homeopathic products occupy a unique position where they’re acknowledged by the FDA as a category of drugs, yet many homeopathic manufacturers make claims that wouldn’t survive scrutiny under standard FDA drug approval processes. The settlement sends a message that even if a product is labeled “homeopathic,” it cannot make false claims about FDA approval status, ingredient safety, or manufacturing standards.
Looking forward, consumers should be cautious about homeopathic products that make claims about homeopathic status without clear FDA language, that fail to list ingredients, or that use vague regulatory language. The Similasan case demonstrates that false homeopathic labeling can result in class action liability, which may encourage other manufacturers to be more careful about their marketing claims. However, it also shows that accountability is typically financial rather than criminal, and settlements may not include mandates to change future product labels—making ongoing consumer vigilance important.
Conclusion
The Similasan $3.575 million class action settlement was approved by a federal court in Colorado on July 17, 2025, and resolved allegations that the company falsely marketed eye drops as homeopathic remedies without proper FDA approval, while also failing to meet manufacturing standards and properly disclosing ingredients like silver sulfate. Nearly 100,000 claims were filed through the settlement, and eligible class members received approximately $14.63 per product purchased during the September 11, 2017 to February 20, 2025 coverage period, distributed through virtual prepaid card, direct deposit, or check.
If you purchased Similasan, CVS homeopathic eye drops, or Walgreens homeopathic eye drops during the covered period but have not yet received a settlement payment, the claim deadline of October 15, 2025 has passed, and you would no longer be eligible for compensation under this settlement. For anyone interested in staying informed about similar class action settlements in the future, regularly checking class action settlement websites and signing up for claim notifications can help ensure you don’t miss future deadlines that could put money back in your pocket.